{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:58:31Z","timestamp":1791928711680,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670121"],"award-info":[{"award-number":["81670121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770120"],"award-info":[{"award-number":["81770120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>BCOR (BCL6 corepressor) is an epigenetic regulator gene involved in the specification of cell differentiation and body structure development. Recurrent somatic BCOR mutations have been identified in myelodysplastic syndrome (MDS). However, the clinical impact of BCOR mutations on MDS prognosis is controversial and the response of hypomethylating agents in MDS with BCOR mutations (BCOR<jats:sup>MUT<\/jats:sup>) remains unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 676 MDS patients, 43 patients (6.4%) harbored BCOR mutations. A higher frequency of BCOR mutations (8.7%) was investigated in patients with normal chromosome, compared to 4.2% in patients with abnormal karyotype (<jats:italic>p<\/jats:italic>\u2009=\u20090.040). Compared to the BCOR<jats:sup>WT<\/jats:sup> patients, the BCOR<jats:sup>MUT<\/jats:sup> patients showed a higher ratio of refractory anemia with excess blasts subset (<jats:italic>p<\/jats:italic>\u2009=\u20090.008). The most common comutations with BCOR genes were ASXL1 (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), DNMT3A (<jats:italic>p<\/jats:italic>\u2009=\u20090.114) and TET2 (<jats:italic>p<\/jats:italic>\u2009=\u20090.148). When the hierarchy of somatic mutations was analyzed, BCOR mutations were below the known initial mutations (ASXL1 or TET2) but were above U2AF1 mutations. Transformation-free survival was significantly shorter in BCOR<jats:sup>MUT<\/jats:sup> patients than that in BCOR<jats:sup>WT<\/jats:sup> patients (16 vs. 35\u00a0months; <jats:italic>p<\/jats:italic>\u2009=\u20090.035). RNA-sequencing was performed in bone marrow mononuclear cells from BCOR<jats:sup>MUT<\/jats:sup> and BCOR<jats:sup>WT<\/jats:sup> patients and revealed 2030 upregulated and 772 downregulated genes. Importantly, HOXA6, HOXB7, and HOXB9 were significantly over-expressed in BCOR<jats:sup>MUT<\/jats:sup> patients, compared to BCOR<jats:sup>WT<\/jats:sup> patients. Eight of 14 BCOR<jats:sup>MUT<\/jats:sup> patients (57.1%) achieved complete remission (CR) with decitabine treatment, which was much higher than that in BCOR<jats:sup>WT<\/jats:sup> patients (28.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.036). Paired sequencing results (before and after decitabine) showed three of 6 CR patients lost the mutated BCOR. The median survival of CR patients with a BCOR<jats:sup>MUT<\/jats:sup> was 40\u00a0months, which was significantly longer than that in patients with BCOR<jats:sup>WT<\/jats:sup> (20\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.036). Notably, prolonged survival was observed in three BCOR<jats:sup>MUT<\/jats:sup> CR patients even without any subsequent therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>BCOR mutations occur more frequently in CN MDS patients, predicting higher risk of leukemia transformation. BCOR<jats:sup>MUT<\/jats:sup> patients showed a better response to decitabine and achieved longer post-CR survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13148-021-01157-8","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T10:03:16Z","timestamp":1630317796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome"],"prefix":"10.1186","volume":"13","author":[{"given":"Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Xi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-4774","authenticated-orcid":false,"given":"Ling-Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"1157_CR1","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1182\/blood-2013-02-451757","volume":"121","author":"JP Issa","year":"2013","unstructured":"Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood. 2013;121:3811\u20137.","journal-title":"Blood"},{"key":"1157_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2217\/epi-2018-0195","volume":"11","author":"A Astolfi","year":"2019","unstructured":"Astolfi A, Fiore M, Melchionda F, Indio V, Bertuccio SN, Pession A. BCOR involvement in cancer. Epigenomics. 2019;11:835\u201355.","journal-title":"Epigenomics"},{"key":"1157_CR3","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41467-019-09250-6","volume":"10","author":"MJ Kelly","year":"2019","unstructured":"Kelly MJ, So J, Rogers AJ, Gregory G, Li J, Zethoven M, et al. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nat Commun. 2019;10:1347.","journal-title":"Nat Commun"},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Chronic Myeloid Disorders Working Group of the international cancer genome consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384\u201395.","journal-title":"N Engl J Med"},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u20139.","journal-title":"Nature"},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616\u201327.","journal-title":"Blood"},{"key":"1157_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241\u20137.","journal-title":"Leukemia"},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1182\/blood-2012-11-469619","volume":"122","author":"F Damm","year":"2013","unstructured":"Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013;122:3169\u201377.","journal-title":"Blood"},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/gcc.22542","volume":"57","author":"K Terada","year":"2018","unstructured":"Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, et al. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis. Genes Chromosomes Cancer. 2018;57:401\u20138.","journal-title":"Genes Chromosomes Cancer"},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1080\/10428194.2018.1543885","volume":"60","author":"N Abuhadra","year":"2019","unstructured":"Abuhadra N, Mukherjee S, Al-Issa K, Usuki K, Kobayashi Y, Tajika K, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leuk Lymphoma. 2019;60:1587\u201390.","journal-title":"Leuk Lymphoma"},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"1157_CR13","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/leu.2017.86","volume":"31","author":"A-K Eisfeld","year":"2017","unstructured":"Eisfeld A-K, Mr\u00f3zek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with deovo acute myeloid leukemia. Leukemia. 2017;31:2211\u20138.","journal-title":"Leukemia"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3324\/haematol.2014.113381","volume":"100","author":"N Bolli","year":"2015","unstructured":"Bolli N, Manes N, McKerrell T, Chi J, Park N, Gundem G, et al. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica. 2015;100:214\u201322.","journal-title":"Haematologica"},{"key":"1157_CR15","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1182\/blood-2011-07-365320","volume":"118","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118:6153\u201363.","journal-title":"Blood"},{"key":"1157_CR16","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"1157_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12967-016-0817-9","volume":"14","author":"L Wu","year":"2016","unstructured":"Wu L, Shi W, Li X, Chang C, Xu F, He Q, et al. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. J Transl Med. 2016;14:66.","journal-title":"J Transl Med"},{"key":"1157_CR18","doi-asserted-by":"publisher","first-page":"32232","DOI":"10.1038\/srep32232","volume":"6","author":"F Xu","year":"2016","unstructured":"Xu F, Zhu Y, He Q, Wu LY, Zhang Z, Shi WH, et al. Identification of micro RNA-regulated pathways using an integration of microRNA-mRNA microarray and bioinformatics analysis in CD34+ cells of myelodysplastic syndromes. Sci Rep. 2016;6:32232.","journal-title":"Sci Rep"},{"key":"1157_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bjh.14455","volume":"176","author":"C Chang","year":"2017","unstructured":"Chang C, Zhao Y, Xu F, Guo J, Zhang Z, He Q, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol. 2017;176:600\u20138.","journal-title":"Br J Haematol"},{"key":"1157_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/leu.2016.2","volume":"30","author":"Q Cao","year":"2016","unstructured":"Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 2016;30:1155\u201365.","journal-title":"Leukemia"},{"key":"1157_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MOH.0000000000000016","volume":"21","author":"AM Zeidan","year":"2014","unstructured":"Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol. 2014;21:123\u201330.","journal-title":"Curr Opin Hematol"},{"key":"1157_CR22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","volume":"131","author":"AM Zeidan","year":"2018","unstructured":"Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131:818\u201321.","journal-title":"Blood"},{"key":"1157_CR23","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, Garcia-Manero G, Batty N, Shan J, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830\u20134.","journal-title":"Cancer"},{"key":"1157_CR24","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Pr\u00e9bet","year":"2011","unstructured":"Pr\u00e9bet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322\u20137.","journal-title":"J Clin Oncol"},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/17474086.2020.1819233","volume":"13","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Zeidan AM. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Expert Rev Hematol. 2020;13:1131\u201342.","journal-title":"Expert Rev Hematol"},{"key":"1157_CR26","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","volume":"6","author":"MR Savona","year":"2019","unstructured":"Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6:e194-203.","journal-title":"Lancet Haematol"},{"key":"1157_CR27","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4:2866\u201370.","journal-title":"Blood Adv"},{"issue":"5","key":"1157_CR28","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/bjh.16628","volume":"189","author":"L Wu","year":"2020","unstructured":"Wu L, Li X, Xu F, Wu D, He Q, Song L, et al. NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy. Br J Haematol. 2020;189(5):982\u20134.","journal-title":"Br J Haematol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-021-01157-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T10:03:39Z","timestamp":1630317819000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-021-01157-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1186\/s13148-021-01157-8","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board\/Ethical Committee of Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}